ON WEDNESDAY, Pfizer filed a complaint in a US District Court in Pennsylvania alleging that Johnson & Johnson (J&J) is using "improper exclusionary tactics" to maintain dominance in the US market for its blockbuster Remicade (infliximab) despite recently introduced competition, according to a report by Reuters.
Pfizer said in the suit that J&J is offering discounts on its Remicade treatment in exchange for essentially excluding Pfizer's drug from insurance coverage, keeping it out of the hands of patients.
J&J said in an e-mailed statement that the lawsuit was without merit and that the company was competing on value and price.
"To date Pfizer has failed to demonstrate sufficient value to patients, providers, payers and employers," said Scott White, President of Janssen Biotech Inc, a unit of J&J.
J&J signed exclusionary contracts with health insurers, hospitals and doctor groups after U.S. regulators approved it as a reasonable substitute for Remicade in 2016, Pfizer said.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Sep 17